Chicago Injury Law Blog

Possibly one of the first Celebrex cases to go before a jury is Rosie Ware v. Pfizer.  Ms. Ware suffered a stroke at age 53. Ms. Ware took Celebrex for over 4 years before suffering her stroke in 2005. Similar to the Vioxx cases, the lawsuit alleges that the defendant's failed to warn doctors and consumers of the potential risks and serious cadiovascular side effects associated with the drug.  Posted In Celebrex
Comments / Questions (1) | Permalink

Last week the Judicial Panel on Multidistrict Litigation assigned all federal Celebrex and Bextra cases to the Northern District of California before the Honorable Charles R. Breyer. The MDL will handle all federal claims arising out of the use, marketing and sales of Celebrex and Bextra. Following in the footsteps of Vioxx, these other cox-2 inhibitors will be grouped together for resolution of pretrial issues and discovery.

Read the Transfer Order here.

Posted In Celebrex
Comments / Questions (0) | Permalink

The more lawsuits that are filed on behalf of those injured by Bextra and Celebrex, the more consolidation seems appropriate. A handful of attorneys in Louisiana are asking the JPML to place Bextra and Celebrex cases in with the Vioxx MDL. Learn about MDL's here. This makes sense considering that the drugs work the same way on the body, cause the same types of cardiovascular events, and present similar questions of fact. The unknown is how this will effect the MDL as a whole. Most likely, the benefits of consolidating these cases will be tempered, if not nulled, by the drag of additional cases in an already large MDL. (See Related Article, Nationwide Bextra and Celebrex Lawsuits Requested to be Consolidated and Transferred to Louisiana Federal Court)

Posted In Bextra , Celebrex , Vioxx
Comments / Questions (0) | Permalink